Influence of Five Potential Anticancer Drugs on Wnt Pathway and Cell Survival in Human Biliary Tract Cancer Cells

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2012 Jan 3

PMID 22211101

Citations 11

Authors

Julia Wachter

Daniel Neureiter

Beate Alinger

Martin Pichler

Julia Fuereder

Christian Oberdanner

Pietro Di Fazio

Matthias Ocker

Frieder Berr

Tobias Kiesslich

Affiliations

Soon will be listed here.

Abstract

Background: The role of Wnt signalling in carcinogenesis suggests compounds targeting this pathway as potential anti-cancer drugs. Several studies report activation of Wnt signalling in biliary tract cancer (BTC) thus rendering Wnt inhibitory drugs as potential candidates for targeted therapy of this highly chemoresistant disease.

Methods: In this study we analysed five compounds with suggested inhibitory effects on Wnt signalling (DMAT, FH535, myricetin, quercetin, and TBB) for their cytotoxic efficiency, mode of cell death, time- and cell line-dependent characteristics as well as their effects on Wnt pathway activity in nine different BTC cell lines.

Results: Exposure of cancer cells to different concentrations of the compounds results in a clear dose-dependent reduction of viability for all drugs in the order FH535 > DMAT > TBB > myricetin > quercetin. The first three substances show high cytotoxicity in all tested cell lines, cause a direct cytotoxic effect by induction of apoptosis and inhibit pathway-specific signal transduction in a Wnt transcription factor reporter activity assay. Selected target genes such as growth-promoting cyclin D1 and the cell cycle progression inhibitor p27 are down- and up-regulated after treatment, respectively.

Conclusions: Taken together, these data demonstrate that the small molecular weight inhibitors DMAT, F535 and TBB have a considerable cytotoxic and possibly Wnt-specific effect on BTC cell lines in vitro. Further in vivo investigation of these drugs as well as of new Wnt inhibitors may provide a promising approach for targeted therapy of this difficult-to-treat tumour.

Citing Articles

Miniaturization of the Clonogenic Assay Using Confluence Measurement.

Mayr C, Beyreis M, Dobias H, Gaisberger M, Pichler M, Ritter M Int J Mol Sci. 2018; 19(3).

PMID: 29510509 PMC: 5877585. DOI: 10.3390/ijms19030724.

Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks.

Xu S, Zhan M, Wang J Cell Death Discov. 2017; 3:17069.

PMID: 29188076 PMC: 5702855. DOI: 10.1038/cddiscovery.2017.69.

Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers.

Mayr C, Beyreis M, Wagner A, Pichler M, Neureiter D, Kiesslich T Biomed Res Int. 2016; 2016:4805270.

PMID: 27957497 PMC: 5120202. DOI: 10.1155/2016/4805270.

Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients.

Urbas R, Mayr C, Klieser E, Fuereder J, Bach D, Stattner S Int J Mol Sci. 2016; 17(12).

PMID: 27941621 PMC: 5187853. DOI: 10.3390/ijms17122053.

Wnt signaling inhibitor FH535 selectively inhibits cell proliferation and potentiates imatinib-induced apoptosis in myeloid leukemia cell lines.

Suknuntha K, Thita T, Togarrati P, Ratanachamnong P, Wongtrakoongate P, Srihirun S Int J Hematol. 2016; 105(2):196-205.

PMID: 27766528 DOI: 10.1007/s12185-016-2116-x.

References

Boly R, Gras T, Lamkami T, Guissou P, Serteyn D, Kiss R . Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int J Oncol. 2011; 38(3):833-42. DOI: 10.3892/ijo.2010.890. View

Behrens J, Lustig B . The Wnt connection to tumorigenesis. Int J Dev Biol. 2004; 48(5-6):477-87. DOI: 10.1387/ijdb.041815jb. View

Kim P, Plescia J, Clevers H, Fearon E, Altieri D . Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003; 362(9379):205-9. DOI: 10.1016/S0140-6736(03)13910-4. View

Kumamoto T, Fujii M, Hou D . Akt is a direct target for myricetin to inhibit cell transformation. Mol Cell Biochem. 2009; 332(1-2):33-41. DOI: 10.1007/s11010-009-0171-9. View

Yde C, Frogne T, Lykkesfeldt A, Fichtner I, Issinger O, Stenvang J . Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT. Cancer Lett. 2007; 256(2):229-37. DOI: 10.1016/j.canlet.2007.06.010. View

Czekanska E . Assessment of cell proliferation with resazurin-based fluorescent dye. Methods Mol Biol. 2011; 740:27-32. DOI: 10.1007/978-1-61779-108-6_5. View

Handeli S, Simon J . A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther. 2008; 7(3):521-9. DOI: 10.1158/1535-7163.MCT-07-2063. View

Cadigan K, Nusse R . Wnt signaling: a common theme in animal development. Genes Dev. 1998; 11(24):3286-305. DOI: 10.1101/gad.11.24.3286. View

Seldin D, Landesman-Bollag E, Farago M, Currier N, Lou D, Dominguez I . CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem. 2005; 274(1-2):63-7. DOI: 10.1007/s11010-005-3078-0. View

10.

Barker N, Clevers H . Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006; 5(12):997-1014. DOI: 10.1038/nrd2154. View

11.

Kelleher F, Fennelly D, Rafferty M . Common critical pathways in embryogenesis and cancer. Acta Oncol. 2006; 45(4):375-88. DOI: 10.1080/02841860600602946. View

12.

Hopfner M, Schuppan D, Scherubl H . Targeted medical therapy of biliary tract cancer: recent advances and future perspectives. World J Gastroenterol. 2008; 14(46):7021-32. PMC: 2776833. DOI: 10.3748/wjg.14.7021. View

13.

Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, OBrien S . CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010; 70(24):10288-98. DOI: 10.1158/0008-5472.CAN-10-1893. View

14.

Gordon M, Nusse R . Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006; 281(32):22429-33. DOI: 10.1074/jbc.R600015200. View

15.

Gao Y, Wang H . Casein kinase 2 Is activated and essential for Wnt/beta-catenin signaling. J Biol Chem. 2006; 281(27):18394-400. DOI: 10.1074/jbc.M601112200. View

16.

Kaminska B, Ellert-Miklaszewska A, Oberbek A, Wisniewski P, Kaza B, Makowska M . Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells. Int J Oncol. 2009; 35(5):1091-100. DOI: 10.3892/ijo_00000424. View

17.

Tapia J, Torres V, Rodriguez D, Leyton L, Quest A . Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci U S A. 2006; 103(41):15079-84. PMC: 1622780. DOI: 10.1073/pnas.0606845103. View

18.

Duncan J, Litchfield D . Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta. 2007; 1784(1):33-47. DOI: 10.1016/j.bbapap.2007.08.017. View

19.

Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M . Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol. 2005; 27(4):973-80. View

20.

Huang H, He X . Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol. 2008; 20(2):119-25. PMC: 2390924. DOI: 10.1016/j.ceb.2008.01.009. View